Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DPII: Discovery Partners Int'l -- Ignore unavailable to you. Want to Upgrade?

To: Bio-Newbie who wrote (63)	4/23/2006 7:03:27 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 111

Ah! It hope that Infinity has done plenty of that. On the surface, "proprietary molecule" ipi-504 seems awfully close to kos-953 (17-AAG). And yet you have a company like Ariad practically claiming NF-kB for itself--why don't they sue MLNM over Velcade too?! edit, found this sec.edgar-online.com On June 26, 2002, Ariad Pharmaceuticals, Inc. sent us and approximately 50 other parties a letter offering a sublicense for the use of U.S. Patent No. 6,410,516 (which was recently issued and which is exclusively licensed to Ariad). We have serious questions concerning the validity of this patent. However, if Ariad sued us for infringement of this patent, and the patent was found to be valid and we were found to be infringing, we could be required to pay royalties based on the U.S. sales of VELCADE, which would reduce our profits on these sales and which could have a material adverse effect on our business. but that's pretty old news In any event, I hope that Kosan does not sue Infinity after my shares convert.